Form 4: Black Diamond Therapeutics Director Acquires Stock Options

Director Garry E. Menzel acquired stock options in Black Diamond Therapeutics, Inc. on June 6, 2024.

Summary

• Garry E. Menzel, a director of Black Diamond Therapeutics, Inc., filed a Form 4 on June 6, 2024, reporting a transaction.
• The transaction involved the acquisition of stock options, specifically the right to buy 30,550 shares of common stock at an exercise price of $4.65.
• These options vest fully on the earlier of June 6, 2025, or the Issuer's next annual meeting of stockholders, contingent upon continued service.
• Following the reported transaction, Menzel directly owns 30,550 derivative securities.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing a stock option grant to a director. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about insider transactions.

Future Outlook

The stock options vest on the earlier of June 6, 2025, or the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

• The acquisition of stock options by a director may signal confidence in the company's future prospects, potentially impacting shareholder sentiment.

Key Dates